Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers

Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Lung and Upper Aerodigestive Cancer
Sponsor
National Cancer Institute (NCI)
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02123849
This randomized phase II trial studies the safety and effects of acetylsalicylic acid (aspirin) taken continuously or intermittently on gene expression in the nasal tissue of current smokers. Smokers are at increased risk of developing lung cancer. Acetylsalicylic acid may be useful in preventing lung cancer.
Intervention
Aspirin, Laboratory Biomarker Analysis, Placebo
Condition
Lung Carcinoma, Tobacco Use Disorder
Investigators
Linda Garland

See list of participating sites